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M I C R O B I O L O G Y
Evolutionary adaptation in fucosyllactose uptake 
systems supports bifidobacteria-infant symbiosis
Mikiyasu Sakanaka1*†, Morten Ejby Hansen2*, Aina Gotoh3, Toshihiko Katoh3, Keisuke Yoshida4, 
Toshitaka Odamaki4, Hiroyuki Yachi1, Yuta Sugiyama1, Shin Kurihara1‡, Junko Hirose5, 
Tadasu Urashima6, Jin-zhong Xiao4, Motomitsu Kitaoka7, Satoru Fukiya8, Atsushi Yokota8,  
Leila Lo Leggio9, Maher Abou Hachem2§, Takane Katayama1,3§
The human gut microbiota established during infancy has persistent effects on health. In vitro studies have suggested 
that human milk oligosaccharides (HMOs) in breast milk promote the formation of a bifidobacteria-rich microbiota 
in infant guts; however, the underlying molecular mechanism remains elusive. Here, we characterized two func-
tionally distinct but overlapping fucosyllactose transporters (FL transporter-1 and -2) from Bifidobacterium longum 
subspecies infantis. Fecal DNA and HMO consumption analyses, combined with deposited metagenome data 
mining, revealed that FL transporter-2 is primarily associated with the bifidobacteria-rich microbiota formation in 
breast-fed infant guts. Structural analyses of the solute-binding protein (SBP) of FL transporter-2 complexed with 
2′-fucosyllactose and 3-fucosyllactose, together with phylogenetic analysis of SBP homologs of both FL transporters, 
highlight a unique adaptation strategy of Bifidobacterium to HMOs, in which the gain-of-function mutations 
enable FL transporter-2 to efficiently capture major fucosylated HMOs. Our results provide a molecular insight 
into HMO-mediated symbiosis and coevolution between bifidobacteria and humans.
INTRODUCTION
The gut microbiota (GM) is intimately associated with health and 
disease of the host, and both the composition and metabolic output 
of this community are influenced by diet (1). As nondigestible dietary 
and host-derived glycans are the primary metabolic resources for 
bacteria in the lower intestines (2), gaining insights into the molecular 
basis of how different microbes adapt to specific glycans to thrive in 
this ecosystem is of particular importance. We have been focusing 
on the formation of the GM during infancy because the most marked 
microbiota changes occur at the onset and termination of breast- 
feeding (3). Understanding the molecular basis of shaping early life 
GM offers a promising avenue for establishing healthy gut community 
within the critical window that affects a lifelong health outcome (4, 5).
Beside essential nutrients, infant diet or mothers’ milk contains 
nondigestible oligosaccharides with a degree of polymerization of ≥3 
[collectively termed human milk oligosaccharides (HMOs)], which 
are the third most abundant component after lactose (Lac) and lipids 
(6, 7). Twelve structures listed in fig. S1 account for >90% of total HMOs 
by weight (8), with 2′-fucosyllactose (2′-FL) and 3-fucosyllactose 
(3-FL) being abundantly present. Note that 2′-FL is present at a rel-
atively higher concentration than 3-FL in milk from secretor mothers, 
while 2′-FL or H antigen (Fuc1-2Gal disaccharide motif) is absent 
and the amount is generally compensated by 3-FL in nonsecretor 
mother’s milk [FUT2−/− (fucosyltransferase 2 gene)] (6). The GM of 
breast-fed infants is dominated by bifidobacteria. The abundance 
and prevalence of bifidobacteria in neonatal guts are attributed to their 
unique ability to catabolize HMOs (9, 10). The glycosidase enzymol-
ogy of HMO catabolism by infant gut–associated bifidobacteria, 
represented by Bifidobacterium longum subsp. longum (B. longum), 
Bifidobacterium longum subsp. infantis (B. infantis), Bifidobacterium 
breve, and Bifidobacterium bifidum, is relatively well understood 
(9, 10). B. bifidum and some strains of B. longum initiate HMO deg-
radation extracellularly using cell surface–attached glycosidases, 
thereby sharing the degradants among other bifidobacteria (11), 
while the other bifidobacteria import intact oligosaccharides that 
are subsequently degraded intracellularly (9, 10). In either case, up-
take of intact or partially degraded HMOs is a pivotal metabolic 
feature. Despite the importance of oligosaccharide uptake for com-
petitiveness and glycan cross-feeding in the gut ecosystem (11), in-
sight into HMO uptake by bifidobacteria is conspicuously limited 
(12–16). The study reported by Mills and co-workers hinted at the 
preference of B. infantis for HMO import by ATP-binding cassette 
(ABC)–type transporters based on genomic sequencing and glycan 
array analysis of ABC transporter–associated solute-binding proteins 
(SBPs) (17, 18). The data obtained using these techniques is, however, 
not sufficient to reliably assign the specificity or the physiological 
relevance of individual transporters to GM formation. Recently, two 
studies used genomics approaches to identify the transporter for 
2′-FL and other fucosylated HMOs in B. longum (12) and B. breve (14). 
Nonetheless, the mechanistic basis underlying the substrate preference 
and in vivo physiological role of the transporters are largely un-
known, although 2′-FL has been commercialized to improve infant 
formula.
Here, we reveal and comprehensively analyze two functionally 
distinct but overlapping FL transporters from B. infantis and highlight 
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the correlations between gene occurrence, HMO consumption, and 
establishment of a bifidobacteria-rich microbiota in breast-fed 
infant guts. We also provide a structural rationale for the differen-
tial recognition of the major HMOs 2′-FL and 3-FL by the two 
transporter-associated SBPs. Our findings underscore the key role 
of oligosaccharide transporters in the coevolution of Bifidobacterium 
with humans as reflected by the diversification of HMO transporters 
and adaptive expansion of their ligand range to span dominant HMO 
structures.
RESULTS
A platform to evaluate substrate specificities  
of HMO transporters
We have developed an in vivo system for evaluating HMO trans-
porter specificities. B. longum 105-A originally has a lacto-N-biosidase 
(LnbX) and lacto-N-biose I/galacto-N-biose transporter (GltABC) 
for assimilation of the prime HMO core structure lacto-N-tetraose 
(LNT) (fig. S1) (15, 19). Starting from the recently constructed B. longum 
105-A lnbX strain (20), we disrupted gltA by markerless gene 
replacement (fig. S2) to create the lnbX gltA double mutant. 
Next, this strain was transformed with a plasmid encoding intracel-
lular exo-glycosidases required for hydrolyzing all glycosidic linkages 
found in HMOs (Fig. 1, A and B). The functionality of these exo- 
glycosidases in the resulting strain MS554 was verified using cell-
free extracts (fig. S3A), while lacking HMO uptake systems was 
consistent with inability to use purified HMO mixture as the carbon 
source (Fig. 1C). The results qualify the strain MS554 as a useful 
model host for systematically analyzing in vivo specificity of HMO 
transporters.
Using this strain, we expressed two paralogous ABC transporters 
from B. infantis JCM 1222T [=American Type Culture Collection 
(ATCC) 15697T] (locus tag numbers Blon_0341–0343 and Blon_2202–
2204; GenBank accession no. CP001095.1), which have been annotated 
as fucosyllactose (FL) transporters with the same specificity, based 
on shared SBP sequence identity (60%) and hits from glycan array 
analysis (Fig. 1D) (17). These transporters conferred increased growth 
on the purified HMO mixture, while growth on Lac was indistinguish-
able from the control strain harboring an empty vector (Fig. 1C). 
2′-FL and 3-FL were the first HMOs to be consumed by the two 
recombinant strains, while no apparent assimilation was observed 
for the control strain (Fig. 1E). The transporter encoded by Blon_2202–
2204 was distinguished from Blon_0341–0343 by conferring utilization 
of lactodifucotetraose (LDFT) and lacto-N- fucopentaose (LNFP) I, 
consistent with higher cell density attained by the Blon_2202–2204–
expressing strain (Fig. 1C). The concentrations of other HMOs, i.e., 
LNT, lacto-N-neotetraose (LNnT), LNFP II/III, lacto-N-difucohexaose 
(LNDFH) I, and LNDFH II, seemed to be invariant during the incu-
bation periods (Fig. 1E). The observed HMO uptake was verified by 
growth on 2′-FL, 3-FL, LDFT, or LNFP I as a sole carbon source 
(fig. S3B). Both the strains expressing Blon_0341–0343 [hereafter 
denoted as FL transporter-1 (SBP name: FL1-BP)] and Blon_2202–
2204 [FL transporter-2 (SBP name: FL2-BP)] grew on 2′-FL and 
3-FL, but the strain with FL transporter-2 additionally grew on 
LDFT and LNFP I. These results established the power of this 
approach to evaluate in vivo HMO uptake. Another key con-
clusion is that FL transporter-1 and -2 have distinct but overlapping 
preferences for HMOs, which was not evident from previous 
reports (12, 17).
Both FL transporter-1 and -2 contribute to the growth  
of B. infantis JCM 1222T on major fucosylated HMOs
We then inactivated either or both of the two transporters of B. infantis 
JCM 1222T (Fig. 2A). Single markerless disruption of FL transporter-1 
(Blon_0341–0343) or FL transporter-2 (Blon_2202–2204) was 
attained, but the double markerless disruption was not successful. 
Instead, a double mutant was obtained by insertional inactivation of 
the FL2-BP gene (Blon_2202::pMSK101) with FL transporter-1–
disrupted background (Blon_0341–0343). Consequently, four mu-
tants were used for the growth phenotypic assay: Blon_0341–0343 
(referred to as FL1), Blon_2202–2204 (FL2), Blon_2202::pMSK101 
(FL2-BPINS), and Blon_0341–0343 Blon_2202::pMSK101 (FL1 
FL2-BPINS, double mutant) (Fig. 2A).
Wild-type (WT) and the four mutants of B. infantis grew at similar 
rates on galactose (Gal) (Fig. 2B). The FL transporter-1 single mu-
tant (FL1) showed growth retardation on both 2′-FL and 3-FL, 
while FL transporter-2 single mutants (FL2 and FL2-BPINS) did 
not. Growth of the FL transporter-1 and -2 double mutant (FL1 
FL2-BPINS) was abolished for 2′-FL and severely impaired for 3-FL. 
The results demonstrated that the 2′-FL and 3-FL transport activity 
of B. infantis JCM 1222T in culture medium depends primarily on 
FL transporter-1 and secondarily on FL transporter-2. The growth 
ability on LDFT was lost for FL transporter-2 single mutants (FL2 
and FL2-BPINS) and FL1 FL2-BPINS double mutant. FL1 showed 
slightly retarded growth on LDFT, despite the fact that FL transporter-1 
is not involved in LDFT uptake (Fig. 1E and fig. S3B). In the medium 
supplemented with LNFP I, all B. infantis variants grew well, except 
for the FL2 strain. Growth of both FL2-BPINS and FL1 FL2-BPINS 
strains on LNFP I medium was unexpected. These results did not 
seem to be caused by reversion to WT genome structure at the FL 
transporter-2 locus, as the cells retained spectinomycin (Sp) resistance 
after 24 hours of incubation. Because FL2-BPINS mutants have intact 
genes for the membrane components, other SBPs encoded at different 
loci, which likely contribute to the limited growth of the ΔFL2 strain 
on LNFP I of FL2 strain, might compensate for FL2-BP in these 
mutants. Nonetheless, the above results indicate that FL transporter-2 
plays an important role in LNFP I utilization by B. infantis.
No obvious growth difference on purified HMO mixture was 
observed between WT and the four mutants (Fig. 2B), although 
2′-FL, 3-FL, LDFT, and LNFP I account for approximately 50% of 
the purified HMO mixture by weight (see the HMO concentrations at 
0 hours of incubation in Fig. 1E). However, in competition between 
the WT and the double mutant (FL1 FL2-BPINS) on 2′-FL– and 
purified HMO mixture–supplemented media, the WT strain outgrew 
the mutant by three and two orders of magnitude (P = 8.14 × 10−10 
and P = 3.30 × 10−6, respectively, Student’s two-tailed t test; Fig. 2C). 
This effect was specific for HMOs, as both strains grew indistinguish-
ably in competition for galactooligosaccharides (GOSs) (P = 0.18). 
Collectively, these results suggest that FL transporter-1 and -2 are 
pivotal fitness factors for B. infantis to prevail in an HMO-rich 
ecological niche.
Ligand binding and structural basis of FL recognition
Binding parameters
Thermodynamics and affinity for ligand binding of FL1-BP and 
FL2-BP were examined by isothermal titration calorimetry (ITC) 
and surface plasmon resonance (SPR) analyses (fig. S4). Binding of 
fucosyllactose ligands to FL1-BP and FL2-BP was driven by a favor-
able change in enthalpy, which was compensated by an unfavorable 
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Fig. 1. A platform for evaluating in vivo substrate specificity of HMO transporters. Specificity of the two candidate HMO transporters from B. infantis was analyzed 
by their heterologous expression in the pMSK65-harboring B. longum 105-A lnbX gltA, the strain expressing intracellular HMO-degrading enzymes but deficient in growth 
on purified HMO mixture. (A) E. coli–Bifidobacterium shuttle vector pMSK65 carrying the genes encoding intracellular HMO-degrading exo-glycosidases from B. infantis. 
(B) B. longum 105-A lnbX gltA strain with pMSK65 as a host for evaluating in vivo specificity of HMO transporters. The candidate gene cluster (shown in red) is introduced 
into the host using a compatible plasmid. (C) Growth of the recombinant B. longum strain with an empty vector (open circles) or with the plasmid expressing FL transporter-1 
(locus tags Blon_0341–0343, blue squares) or FL transporter-2 (locus tags Blon_2202–2204, green squares) in medium supplemented with 0.5% (w/v) purified HMO mixture 
or Lac. Experiments were technical duplicates, and data are means ± SD. OD600, optical density at 600 nm. (D) Gene organization of candidate FL transporter paralogs from 
B. infantis JCM 1222T analyzed in this study. TMDs, transmembrane domains; aa, amino acid; bp, base pair. (E) Changes in the concentration of each HMO in culture supernatant 
during growth on 0.5% (w/v) purified HMO mixture. Experiments were technical triplicates, and data are means ± SD. The symbols are the same as in (C). Sugars are 
depicted according to the nomenclature committee of the Consortium for Functional Glycomics (www.functionalglycomics.org/static/consortium/consortium.shtml).
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entropy change (Table 1). No measurable heat signals were observed 
for the other ligands at the tested concentrations (fig. S4). The Kd (dis-
sociation constant) value of FL1-BP for 2′-FL (≈10 M) was compa-
rable to those of FL2-BP for 2′-FL and 3-FL (5 to 6 M). By contrast, the 
affinity of FL2-BP to LDFT was lower (≈200 M), which is in accord 
with the SPR binding data (Table 1). Despite the similar Kd values, a 
1.7-fold higher enthalpy change was observed for FL1-BP as com-
pared to FL2-BP in 2′-FL binding, indicative of higher hydogen-bonding 
density by FL1-BP.
Overall structure of FL2-BP
FL1-BP crystals were not obtained despite intensive screening efforts, 
but the crystal structures of FL2-BP complexed with 2′-FL and 3-FL 
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organization at the genomic loci for the two FL transporters in B. infantis JCM 1222T variants. (B) Growth of WT and mutant B. infantis strains on 0.5% (w/v) Gal, 2′-FL, 3-FL, 
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mixture. The population of each strain was determined by quantitative polymerase chain reaction (qPCR), and the relative abundance (%) of WT (white bar) and double mutant 
(gray bar) is shown. Experiments were biological triplicated, and the data are means ± SD. Student’s two-tailed t test was used for evaluating statistical significance.
 o
n
 O
ctober 21, 2019
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Sakanaka et al., Sci. Adv. 2019; 5 : eaaw7696     28 August 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
5 of 15
were solved at 1.3 and 1.4 Å, respectively (table S1). FL2-BP adopts 
a canonical SBP fold [cluster B according to the structural classification 
system (21)], which comprises two domains of different size joined 
by a tripartite hinge region, with the ligand binding site located at 
the domain interface (Fig. 3A). Domain 1 (33–161; 322–373) is 
formed by eight  helices and five  strands. Domain 2 (165–318; 
378–460) consists of nine  helices and seven  strands, and the 
hinge region comprises two short loops spanning the center of the 
two domains (162–164; 319–321) and the loop 374–377. A DALI 
server search (22) for structural comparisons with Protein Data Bank 
(PDB) proteins identified the SBP of the lacto-N-biose I/galacto-N-biose 
transporter from B. longum (GltA) (15) [PDB code 2z8f; z score = 38.5; 
root mean square deviation (RMSD) = 2.5 Å for 381 aligned C atoms 
and 17% sequence identity] as the structurally most related ortho-
log to FL2-BP. The second best hit is the -1,2-glucooligosaccharide– 
binding SBP (23) from Listeria innocua (PDB code 5yse; z score = 37.4; 
RMSD = 2.7 Å for 372 aligned C atoms and 21% sequence identity).
Ligand binding site
The structures of FL2-BP complexed with 2′-FL and 3-FL showed 
well-defined densities for these trisaccharides in the binding site 
comprising a deep but open pocket. Comparison of the binding site 
in both complexes reveals the recognition of the same structural 
motif involving Fuc-[Gal/Glc] (Fuc, fucose; Glc, glucose; fig. S5), 
which explains the basis for the dual recognition of 2′-FL and 3-FL 
with similar binding parameters (Table 1). The Fuc moiety occupies 
the same position at the bottom of the binding site (designated 1′), 
together with the connected sugar ring (Gal in 2′-FL or Glc in 3-FL) 
occupying position 1 (Fig. 3, B and C, and fig. S5). The reducing end Glc 
of 2′-FL and the nonreducing end Gal of 3-FL occupy position 2, 
but these sugar units are shifted about 50° in the plane of the rings.
The three OH groups of the Fuc at position 1′ are recognized in 
both complexes by polar contacts to G321, S212, E284, S112, N114, 
and K115, but the latter is only in the 2′-FL complex (table S2). The 
endocyclic oxygen (O5) of the Fuc is at hydrogen-bonding distance from 
the OH group of Y59, which, together with F92 and the aliphatic 
side chain of K115, encages the methyl group, thereby contributing 
to the strict recognition of the Fuc moiety. Position 1 is defined by 
aromatic stacking of either the Gal or Glc moiety onto W286 from 
domain 2, while polar contacts are provided by both domains of 
FL2-BP (Fig. 3, B and C, and fig. S6, A and B). At position 1, Gal of 
2′-FL and Glc of 3-FL (modeled in both  and  anomers) make 
contacts to S60, while C3-OH of Gal and C2-OH of Glc form poten-
tial polar contacts to the amide nitrogen of S322 and the side chains 
of S322 and D161 (table S2). The dual recognition of Gal of 2′-FL or Glc 
of 3-FL at position 1 is possible because of the plasticity of Q63 and the 
rearrangement of the solvent-mediated hydrogen-bonding networks 
according to the bound ligand. An additional polar contact to endo-
cyclic O5 of Glc at position 1 in the 3-FL complex is also possible. In 
contrast to the extensive recognition of the Fuc-[Gal/Glc] motif, the 
density of direct protein-ligand polar interaction at position 2 is 
markedly lower. The only potential hydrogen bonds in the 2′-FL complex 
are between Glc and A88, while in the 3-FL complex E284 interacts 
with the Gal unit. Overall, the structural mimicry between Fuc-
[Gal/Glc] motifs of 2′-FL and 3-FL occupying positions 1′ and 1 as 
well as the space to accommodate the sugar rings in different orien-
tations and the concomitant rearrangement of water-mediated 
hydrogen-bonding networks at position 2 provide a structural rationale 
for the observed dual specificity. The open binding site, especially 
around position 2, is likely to be key for the accommodation of 
LDFT and LNFP I, albeit at a lower affinity.
Binding site conservation and functional signatures of FL-BPs
To unveil the structural elements associated with the different binding 
specificities, we analyzed sequences of FL1-BP and FL2-BP homologs 
(fig. S6, A to C). A striking difference was observed between the 
conservation patterns in the binding site residues that recognize the 
Lac moiety and those that interact with Fuc in FL2-BP. Thus, S60, 
Q63, A88, S112, D161, W286, G321, and S322 are invariant across 
the homologs. Six of these residues interact with the Lac unit, while 
S112 and G321 recognize the Fuc moiety (fig. S6, A and B). By contrast, 
all of the five variable residues (Y59, N114, K115, S212, and E284) 
are involved in Fuc recognition. The FL-BP sequences segregate 
into four clusters (I to IV) in phylogeny with divergence of the Fuc 
binding residues. FL1-BP and FL2-BP from B. infantis JCM 1222T 
belong to cluster IV and cluster II, respectively (fig. S6C). This analysis 
highlights the sequence signatures underpinning the observed spec-
ificity difference between FL1-BP and FL2-BP.
FL-BP homologs are enriched in B. infantis genomes but are 
also sporadically encountered in other infant gut–associated 
bifidobacterial species
BlastP analysis using the National Center for Biotechnology Information 
(NCBI) genomic database (www.ncbi.nlm.nih.gov/) revealed limited 
Table 1. Binding parameters of FL1-BP and FL2-BP to mono- and difucosyllactose determined by ITC and SPR analysis.  
Protein Ligand
ITC* SPR
Ka
(×105 M−1)
Kd
(M)
G0
(kcal mol−1)
H
(kcal mol−1)
−TS0
(kcal mol−1)
S0 (cal 
K−1 mol−1)
n
(site)
Kd
(M)† Rmax‡ χ 
2 §
FL1-BP 2′-FL 1.05 ± 0.23 9.75 −6.8 −23.6 ± 0.5 16.8 −56.3 0.85 ± 0.14 9.0 ± 0.7 14.7 0.09
FL2-BP
2′-FL 1.86 ± 0.12 5.40 −7.2 −14.2 ± 0.7 7.0 −23.6 0.90 ± 0.04 9.9 ± 1.6 9.3 0.13
3-FL 1.69 ± 0.11 5.95 −7.1 −14.0 ± 0.4 6.9 −23.2 1.12 ± 0.14 5.9 ± 0.5 10.2 0.06
LDFT 0.05 ± 0.00 191.11 −5.1 −6.8 ± 0.5 1.7 −5.7 1.02 ± 0.02 163.1 ± 25.0 12.0 0.24
*Values of association constants (Ka), enthalpy of binding (H), and binding stoichiometry (n) obtained in ITC analysis are expressed as means ± SD of duplicate 
experiments. Dissociation constants (Kd) were calculated from the reciprocal of Ka. The Gibbs free energy change (G0) and the entropy change (S0) were 
calculated from the equations G0 = −RTlnKa and TS0 = H − G0, respectively (R, gas constant; T, absolute temperature).   †The Kd values obtained in the 
SPR analysis are means ± SD of duplicate experiments.   ‡The maximum binding level from the fits to a one-site binding model.   §Statistical goodness of 
the fit to a one-site binding model.
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A
D
C
B
Species/subspecies Occupancy in (sub)species Strain FL1-BP homolog FL2-BP homolog
B. longum subsp. infantis 16/19 strains
JCM 1222T IV II
BIC1206122787 IV II
BIC1307292462 IV II
BIC1401111250 IV II
BIC1401212621a IV II
BIC1401212621b IV II
BIB1401242951 IV II
BIB1401272845a IV II
BIB1401272845b IV II
IN-07 IV II
NCTC 13219 IV II
IN-F29 II
EK3 II
TPY12-1 II
BT1 II
1888B II
B. longum subsp. longum 3/39 strains
SC596 II
JDM301 III
CMCC P0001 III
B. breve   10/89 strains
MCC 1128 IV
MCC 1340 I
BR-06 I
BR-10 I
BR-14 I
BR-15 IV
BR-20 I
BR-21 I
BR-A29 I
BR-I29 IV
B. pseudocatenulatum 6/14 strains
JCM 1200T I
CA-C29 I
CA-K29a I
CA-K29b I
1896B I
TM10-1 I
B. kashiwanohense 2/2 strains PV20-2 IJCM 15439T III
B. longum subsp. suis 1/2 strains BSM11-5 I
90% ≤ Identity ≤ 100% 61% < Identity < 90% Identity ≤ 61%
Fig. 3. Structure of 2’-FL- or 3-FL-complexed SBP of FL transporter-2 (FL2-BP) and distribution of FL-BP homologs among gut microbes. (A) Cartoon model of the overall structure 
of FL2-BP complexed with 2′-FL. Domain 1 and domain 2 are in brown and green, respectively. The sugars are depicted in stick models with carbon atoms of Fuc in white, Gal in yellow, Glc 
in blue, and oxygen atoms in red. (B and C) Close-up view of the ligand binding site of FL2-BP in complex with 2′-FL (B) and 3-FL (C). The same colors are used as in (A). (D) Distribution of 
FL1-BP and FL2-BP homologs (>61% identity) among Bifidobacterium species/subspecies. FL1-BP and FL2-BP from B. infantis JCM 1222T were used as queries for BlastP analysis. The cluster 
numbers (I to IV) are indicated based on the phylogenetic analysis shown in fig. S6C. The sequences of B. longum without subspecies identification in the National Center for Biotechnology 
Information (NCBI) database were excluded from the analysis. No close homologs (≥60% identity) were found in the genomes of other bacterial taxa in the NCBI database.
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occurrence of the FL1-BP (cluster IV) and FL2-BP (clusters I to III) 
homologs among bifidobacteria at species and strain levels (Fig. 3D 
and fig. S6C). No close homologs (≥60% identity) were found in 
the genomes of other bacterial taxa. Sixteen of 19 strains of B. infantis 
have close homologs of either FL transporter, and 11 strains have 
both homologs (≥90% identity). In contrast, only 3 of 39 B. longum 
strains have FL2-BP homologs and 2 of them showed moderate 
identity (71%, cluster III) to B. infantis FL2-BP. In the genomes of 
B. breve, close homologs of either FL-BP were found in 10 of 89 strains, 
while Bifidobacterium pseudocatenulatum has FL2-BP homologs in 
6 of 14 strains. In Bifidobacterium kashiwanohense and Bifidobacterium 
longum subsp. suis, FL2-BP homologs were found in two and one 
strains, respectively. The FL2-BP homologs of B. kashiwanohense 
that belong to cluster III showed relatively low identity (71%); 
nonetheless, the gene cluster present in B. kashiwanohense JCM 
15439T (BBKW_1838–1840) conferred the same ability to assimi-
late 2′-FL, 3-FL, LDFT, and LNFP I as FL transporter-2 from 
B. infantis when introduced into MS554 (fig. S6D). Sequences of 
the permease subunits are less divergent (≥90% identity in all the 
clusters), emphasizing the key role of SBPs in dictating uptake 
preference.
The abundance of Bifidobacterium is associated with FL 
transporter genes in breast-fed infant guts
We then analyzed fecal DNA obtained from Japanese subjects com-
prising 36 breast-fed infants and 32 adults. The abundances of 
Bifidobacterium and the FL2-BP homolog, but not the FL1-BP homolog, 
were significantly higher in breast-fed infant stools than in adult 
samples (P < 0.001, Mann-Whitney U test; Fig. 4A). Statistically sig-
nificant positive correlations were detected in the breast-fed infant 
group between the abundances of Bifidobacterium and the FL2-BP 
or FL1/2-BP homolog genes ( = 0.512, P = 0.001 for FL2-BP gene 
and  = 0.501, P = 0.002 for FL1/2-BP genes) (Fig. 4B; Spearman’s rank 
correlation coefficient analysis), while a weak positive correlation was also 
observed between the FL1-BP homolog gene and Bifidobacterium 
( = 0.370, P = 0.026). By contrast, weak or no positive correlation 
was detected between the two groups in the adult samples ( = 0.386, 
P = 0.032 for FL1/2-BP genes). The FL-BP genes were commensurate 
with the in vivo consumption of fucosylated HMOs based on the 
comparative analysis of HMO concentrations in breast milk and infant 
stools from 32 infant-mother pairs (fig. S7). In the fecal samples in 
which either or both FL-BP genes were detected (positive group, 
n = 25), the concentrations of the FL transporter substrates 2′-FL, 
3-FL, LDFT, and LNFP I were lower than those detected in the FL-
BP gene–negative group (n = 7), whereas their concentrations in 
milk did not differ between the two groups (P = 0.0098 versus 
P = 0.2944, Mann-Whitney U test; Fig. 4C). The abundance of the 
FL2-BP gene, but not the FL1-BP gene, negatively correlated with 
the concentrations of 3-FL ( = −0.416, P = 0.018) and LNFP I 
( = −0.551, P = 0.001) in infant stools at statistically significant levels 
(Fig. 4D; Spearman’s rank coefficient analysis).
To support the above results, we have also evaluated the association 
between the abundances of Bifidobacterium and FL-BP genes by 
mining of the deposited metagenome dataset (MG-RAST, accession 
no. qiime:621) (3). The fecal metagenomic data for 83 individuals 
residing in the United States (n = 50), Malawi (n = 18), and Venezuela 
(n = 15), which comprise breast-fed (n = 34) and formula-fed 
(n = 27) infants (≤1 year old) and adults (n = 22, ≥18 years old), 
were used for the analysis. The results revealed that Bifidobacterium 
and both FL-BP genes, especially the FP2-BP gene, are significantly 
enriched in the breast-fed infant group compared to the formula-fed 
infant and adult groups (Fig.  4E). No significant difference 
was observed for the Bifidobacterium abundance in stools of breast-fed 
infants living in the United States (n = 10), Malawi (n = 14), 
and Venezuela (n = 10), whereas both FL-BP genes were more 
abundantly present in the Malawi and Venezuela groups than 
in the U.S. group (Fig. 4F). The abundances of both FL-BP genes 
(especially the FL2-BP gene) and the Bifidobacterium genus in the 
Malawi and Venezuela groups were strongly positively correlated 
(Fig. 4G; Spearman’s rank correlation coefficient analysis). Collectively, 
these results strongly suggest that the presence of FL transporters, 
and in particular the FL2 transporter, is highly relevant to the 
bifidobacteria-rich microbiota formation in the gut of breast-fed 
infants by supporting utilization of major fucosylated HMOs, and 
also suggest evolutionary adaptation of bifidobacteria to HMOs 
(see Discussion).
DISCUSSION
As exemplified by the specific occurrence of red seaweed degrada-
tion and transport genes in the Japanese microbiome, gut bacteria 
display evolutionary adaptation to host diet (24). In addition, a 
key role of transporters in supporting microbial competitiveness 
has been recently proposed based on the ability of two abundant 
GM symbionts with differing oligosaccharide uptake preferences 
to co-grow on dietary xylan (25). Contribution of multiple trans-
porters to human gut colonization was suggested by Maldonado- 
Gómez et al. (26). In the present study, we analyzed two HMO 
transporters from B. infantis to gain insights into the possible 
evolutionary advantages of these transporters with distinct but 
overlapping specificities and to characterize their contribution to 
GM development in breast-fed infants.
Bifidobacterial platform for functional analysis  
of HMO transporters
Bifidobacteria have evolved two strategies for assimilating HMOs 
(9, 10). One is represented by B. bifidum and some B. longum strains 
that use extracellular glycosidase(s) (e.g., -l-fucosidase and LnbX) 
to degrade HMOs to mono- and disaccharides outside the cells and 
then import the degraded sugars and/or share them to other bifido-
bacteria. In contrast, B. breve, B. infantis, and most B. longum 
strains use transporters to directly internalize HMOs and then de-
grade them intracellularly. The extracellular glycosidase-dependent 
type B. bifidum (9, 11) is generally less abundant in the infant GM 
community (14). In our previous study, secretory LnbX-positive 
B. longum was present at 0.2%, on average, of the total B. longum 
population (20). These results suggest that most of the infant gut 
bifidobacteria use transporters for assimilating HMOs. Nonetheless, 
reports on identification and characterization of HMO transporters 
are quite limited, although HMOs comprise more than 100 struc-
tures. The paucity of transporter studies is largely due to the limited 
genetic tools that work in Bifidobacterium. The strain MS554 developed 
in this study serves as a powerful platform for examining in vivo 
specificities of transporters responsible for neutral, fucosylated, and 
sialylated HMO uptake (Fig. 1 and figs. S3 and S6D). This engineered 
strain offers instrumental data for detailed understanding of the 
specificity and interplay between HMO transporters, especially when 
integrated with structural and binding data.
 o
n
 O
ctober 21, 2019
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Sakanaka et al., Sci. Adv. 2019; 5 : eaaw7696     28 August 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
8 of 15
A
Negative Positive 
Co
nc
. 
o
f 
)
lit
er
/g(
 setartsb
us
 retrops
nart
 LF
FL1/2-BP homolog
C Breast milk Infant feces
P = 0.2944
Negative Positive 
Co
nc
.
 
o
f 
FL
 tr
an
sp
or
te
r s
u
bs
tra
te
s 
(g/
g)
FL1/2-BP homolog
FL1-BP
FL2-BP
Correlation coefficient
0 0.60.6
D Infant feces
G
0
4
8
0
0.2
0.4 P = 0.0098
Bifidobacterium FL1-BP homolog FL2-BP homolog
Breast-fed Adult Breast-fed Adult Breast-fed Adult
0
50
100
Ab
un
da
nc
e 
(%
)
0
50
100
0
50
100
P < 0.001P < 0.001 P = 0.121
F
FL1-BP
FL2-BP
FL1- &  
FL2-BP
Genus
Bifidobacterium
Correlation coefficient
0 1.01.0
Breast-fed
***
E )
%(
 ec
nad
n
ubA
100
b
a
b b b
0
50
0
0.05
c
Bifidobacterium FL1-BP homolog FL2-BP homolog
a
0
a
0.05
0.10
b
0.10
)
%(
 ec
nad
n
ubA
100
a
b b
b
0
50
0
0.05
a
Bifidobacterium FL1-BP homolog FL2-BP homolog
a
0
a
0.05
0.10
b
0.10a
***
***
**
***
***
0
20
40
60
80
100
0 20 40 60 80 100
ρ = 0.370, P = 0.026
ρ = 0.070, P = 0.708
B
0
30
60
90
120
150
0 20 40 60 80 100
Adult
ρ = 0.501, P = 0.002
ρ = 0.386, P = 0.032
Ab
un
da
nc
e 
o
f F
L1
-
&
FL
2-
BP
ho
m
ol
og
s 
(%
)
Abundance of Bifidobacterium (%)
0
20
40
60
80
100
0 20 40 60 80 100
ρ = 0.512, P = 0.001
ρ = 0.354, P = 0.051
Ab
un
da
nc
e 
of
 
FL
2-
BP
ho
m
o
lo
g 
(%
)
Abundance of Bifidobacterium (%)
 f
o
 ec
nad
n
ubA
FL
1-
BP
ho
m
ol
og
 (%
)
Abundance of Bifidobacterium (%)
Breast-fed
−
−
 
Fig. 4. The abundance of Bifidobacterium in breast-fed infant guts is associated with FL transporter genes. The results presented here were obtained by analyzing 
Japanese subjects recruited in this study (A to D) and by data mining of a deposited metagenome dataset (MG-RAST, accession no. qiime:621) (3) (E to G). (A) Relative 
abundance (%) of genus Bifidobacterium and two FL-BP homologs in stool DNA of breast-fed infants (n = 36) and adults (n = 31). The copy number of the genes attributable to 
Bifidobacterium 16S ribosomal RNA (rRNA), FL1-BP, and FL2-BP, which was determined by qPCR analysis, was divided by the copies of the 16S rRNA gene attributable to 
total bacteria. Mann-Whitney U test was used for evaluating the statistical significance. The data are shown by box plot, in which the middle bar indicates the median, 
while the top and bottom of the box indicate the third and first quartiles, respectively. Whiskers represent the lowest and highest values within 1.5 times the interquartile 
range from the first and third quartiles, respectively. (B) Spearman’s rank correlation coefficient analysis between the relative abundances of genus Bifidobacterium and 
either (left and middle panels) or both (right panel) of FL-BP genes in the breast-fed infant (orange circles) and adult (purple squares) groups. The data obtained in 
(A) were used for the analysis. (C) The concentrations of 2′-FL, 3-FL, LDFT, and LNFP I (substrates for FL transporter-1 and -2) in breast milk and infant stools (32 mother-infant 
pairs) were compared between FL-BP gene–detected (positive, n = 25) and undetected (negative, n = 7) groups. Mann-Whitney U test was used for evaluating the 
statistical significance. (D) Spearman’s rank correlation coefficient analysis between the relative abundance of the FL1-BP or FL2-BP gene and the fecal concentration of 
each substrate HMO. The data obtained in (C) were used for the analysis, and the results are shown as a heat map. *P < 0.05 and **P < 0.01. Sugars are depicted as in Fig. 1. 
(E and F) The deposited metagenome data of 83 individuals from the United States (n = 50), Malawi (n = 18), and Venezuela (n = 15) were used for the analysis 
(132,556 ± 76,952 reads per sample) (3). The abundances (%) of genus Bifidobacterium and two FL-BP homologs in the fecal samples obtained from breast-fed (n = 34) and 
formula-fed (n = 27) infants (≤1 year old) and adults (n = 22, ≥18 years old) are shown in (E), and those in the fecal samples of breast-fed infants living in the United States 
(n = 10), Malawi (n = 14), and Venezuela (n = 10) are shown in (F). See Materials and Methods for read count and abundance calculation for FL-BP genes. Different letters 
(a, b, and c) indicate statistically significant differences among the three groups (P < 0.05, Mann-Whitney U test with Bonferroni correction). (G) Spearman’s rank correlation 
coefficient analysis between the relative abundances of genus Bifidobacterium and either or both of two FL-BP genes in the breast-fed infant group. The data obtained in 
(F) were used for the analysis, and the results are shown as a heat map. *P < 0.05, **P < 0.01, and ***P < 0.001.
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Fecal occurrence of two FL transporters with distinct but 
overlapping specificities is associated with bifidobacteria-
rich GM formation in breast-fed infant guts
FL transporter-1 and -2 of B. infantis JCM 1222T were assumed to 
have the same specificity (17); however, our results show distinct 
but overlapping specificities of the two transporters (Figs. 1E and 
2B and fig. S3B). FL1-BP and FL2-BP define segregated clades in the 
phylogenetic tree with marked differences in FL binding residues 
(fig. S6, A to C). Notably, residues that recognize 2′-FL and 3-FL are 
also variant in the signature sequences of these clades, e.g., N114, 
K115, and E284 in FL2-BP being replaced with serine, glutamic 
acid, and glycine, respectively, in cluster IV (FL1-BP homologs), al-
though they are invariant or conservatively substituted in clusters 
I to III (FL2-BP homologs). These differences may, in part, explain 
the differential affinity to 3-FL between the two SBPs. The larger 
influence of FL transporter-1 on the in vitro growth on 2′-FL and 
3-FL than FL transporter-2 is intriguing (Fig. 2B). Possible explana-
tions could be differential expression levels of the associated SBPs 
due to codon usage differences (FL1-BP: 45% of GC content; FL2-BP: 
54% of GC content) and lower affinity binding of 3-FL to FL1-BP 
due to the structural mimicry of this ligand to 2′-FL (fig. S5B). 
However, the stool DNA analysis suggests that both of the two FL 
transporters, especially FL transporter-2, provide growth advantage 
for bifidobacteria to selectively dominate breast-fed infant gut eco-
system (Fig. 4, A to D). The possible fitness advantage exerted by FL 
transporters in the HMO-rich environment is also supported by 
metagenome data mining (Fig. 4, E to G), although strong positive 
correlation was observed between Bifidobacterium and FL-BP gene(s) 
for breast-fed infants who live in Malawi and Venezuela, but not in 
the United States.
An evolutionary adaptation of bifidobacteria  
to HMO structures
Bifidobacterium is assumed to have coevolved with their hosts by 
acquiring genes that support proliferation in the digestive tracts of 
mammals, especially humans (27). Notably, considerable acquisition 
of ABC-type carbohydrate transporters by bifidobacteria has been 
proposed (28). Recent findings have also suggested the possible involve-
ment of a single ABC transporter (a homolog of FL2-BP) in FL utilization 
(12, 14). In the present study, we unequivocally reveal how infant 
gut–associated bifidobacteria have adaptively evolved two FL trans-
porters to assimilate two major components, 2′-FL and 3-FL, of HMOs 
in breast-fed infant guts. The 3-FL–transporting activity of FL 
transporter-1 and the observed in vitro impact of the deletion of 
this transporter in B. infantis on LDFT utilization are puzzling but 
possibly explained by a higher expression level of FL1-BP compared 
to FL2-BP, which may compensate for lower affinity of FL1-BP to 
these ligands due to the structural similarity to 2′-FL (fig. S5B). The 
lack of measurable binding of 3-FL and LDFT to FL1-BP in our assay 
does not preclude low-affinity interactions with this SBP. Capture of 
these ligands is unlikely to be physiologically relevant under in vivo 
competition conditions (due to low availability), although the 
ligands can be bound in the lack of competition. By contrast, the 
activity of FL transporter-2 is evidently derived from gain-of-function 
amino acid substitutions, by which FL2-BP evolved to recognize 
both 2′-FL and 3-FL with similar affinity and to recognize LDFT 
and LNFPm I, albeit at lower affinities than the preferred trisaccharides. 
The adaptive mutations are reflected by the statistically significant 
negative correlation observed between the abundance of the FL2-
BP gene, but not the FL1-BP gene, and the concentration of 3-FL in 
infant stools (Fig. 4D). A statistically significant negative correlation 
was also detected between FL2-BP gene abundance and the concen-
tration of LNFP I These findings emphasize the relevance of the measured 
SBP affinities to in vivo transporter preferences. Thus, the gain-of-
function mutations and the broader conservation of FL2-BP genes 
compared to FL1-BP in the genomes of different bifidobacterial species 
represent a possible coevolutionary strategy between Bifidobacterium 
and humans, which is driven by HMOs. Note that this dual specificity 
might enable bifidobacteria to adapt to HMOs synthesized by non-
secretors who do not produce 2′-FL but produce a lot of 3-FL in their 
milk (6). Thus, FL transporter-2 provides a strong fitness advantage 
for specialization for utilization of the major constituents of HMOs.
CONCLUDING REMARKS
The present study combined with previous results (9, 10, 16, 18) have 
deciphered the complete and minimum gene set required for FL 
and LNFP I assimilation in B. infantis (Fig. 5) and expand our un-
derstanding on how other infant gut–associated bifidobacterial 
species use major fucosylated HMOs by either of the FL transporters 
(B. longum, B. breve, B. pseudocatenulatum, and B. kashiwanohense) 
or extracellular -l-fucosidases (B. bifidum) (9). The results obtained 
from fecal DNA and HMO consumption analyses and deposited 
metagenomic data analysis reiterate HMOs as prime mediators in 
the coevolutionary dialog between humans and bifidobacteria. Our 
findings highlight HMO-specific ABC transporters as a key fitness 
factor supporting the adaptation and dominance of bifidobacteria in 
the infant gut ecosystem. Further studies are required to understand 
which additional HMOs and transporters contribute to shaping a 
bifidobacteria-rich GM in infants. Such studies are a necessary pre-
requisite for conducting evidence-based clinical interventions testing 
supplementation of additional HMO ligands in formula milk.
MATERIALS AND METHODS
Chemicals
2′-FL, 3-FL, LDFT, and LNT were from Sigma-Aldrich (St. Louis, 
MO, USA) or as gifts from Glycom A/S (Hørsholm, Denmark). 
LNnT and LNFP I were from Dextra Laboratories (Reading, UK). 
LNFP II, 3′-sialyllactose (3′-SL), and 6′-sialyllactose (6′-SL) were from 
Carbosynth (Berkshire, UK). Melibiose and GOSs were from FUJIFILM 
Wako Pure Chemical (Osaka, Japan). Maltoheptaose was from 
Toronto Research Chemicals (Toronto, ON, Canada). Purity of the 
purchased or gifted sugars is >95% according to material safety data 
sheets. 2-Aminoanthranilic acid and sodium cyanoborohydride were 
from Nacalai Tesque (Kyoto, Japan). HMOs were purified from 
pooled breast milk as described previously (11). The HMOs analyzed 
in this study accounted for >80% of the purified HMO mixture by 
weight, and 2% (w/w) Lac was present as impurity based on high- 
performance liquid chromatography (HPLC) analysis (see below). 
All other chemicals were of analytical grade.
Bacteria and culture conditions
B. infantis JCM 1222T (=ATCC 15697T) and B. kashiwanohense JCM 
15439T were from Japan Collection of Microorganisms (RIKEN 
Bioresource Center, Tsukuba, Japan), while B. longum 105-A was a 
gift from Y. Kano at Kyoto Pharmaceutical University, Japan (currently 
available as JCM 31944 from RIKEN Bioresource Center). For clarity, 
only the locus tag numbers assigned to the ATCC 15697T (Blon_, 
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Fig. 5. Schematic model showing selective growth advantage of bifidobacteria with FL transporter-1 and -2 in the breast-fed infant guts. FL transporters and 
HMO-degrading enzymes are shown with their locus tag numbers of B. infantis ATCC 15697T (GenBank accession no. CP001095.1). Sugars are depicted as in Fig. 1.
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GenBank accession no. CP001095.1) are used to describe the identical 
genes from B. infantis JCM 1222T. Bifidobacteria were anaerobically 
grown at 37°C in Gifu anaerobic medium (GAM; Nissui Pharma-
ceutical, Tokyo, Japan) or in de Man, Rogosa, and Sharpe medium 
(Becton Dickinson, Franklin Lakes, NJ, USA) containing 0.34% (w/v) 
sodium ascorbate and 0.02% (w/v) cysteine-HCl (MRS-CS) supple-
mented with 2% (w/v) Glc. When examining sugar utilization, 
MRS-CS broth was supplemented with 0.5% (w/v) of each sugar. 
Escherichia coli DH5 was used for genetic manipulations. Antibiotics 
and the concentrations used were as follows: chloramphenicol (Cm) 
(2.5 g/ml for bifidobacteria and 10 g/ml for E. coli), Sp (30 g/ml 
for B. longum, 10 g/ml for B. infantis, and 75 g/ml for E. coli), and 
kanamycin (50 g/ml for E. coli). InvivO2 400 (10% CO2, 10% H2, 
and 80% N2; Ruskinn Technology, Bridgend, UK) was used for an-
aerobic cultivation. Growth was monitored by measuring optical 
density at 600 nm (OD600) unless otherwise indicated.
Electrotransformation of B. longum and B. infantis
B. longum 105-A and B. infantis JCM 1222T and their derivatives 
were cultured in 8 ml of GAM. Cells at the exponential phase 
(OD600 = 0.4 to 0.6) were harvested by centrifugation (19,000g, 5 min, 
4°C for B. longum and 5000g, 3 min, 4°C for B. infantis), washed 
twice with the same volume of ice-cold 1 mM ammonium citrate 
(pH 6.0) buffer containing 50 mM sucrose, and resuspended in 
400 l (for B. longum) or 200 l (for B. infantis) of the same solution. 
Then, the cells (50 l) were electroporated with 0.1 to 3.0 g of plasmid 
DNA (<5 l) that was isolated from E. coli DH5 with the Wizard 
Plus SV Minipreps DNA Purification System (Promega, Madison, 
WI). Gene Pulser Xcell (Bio-Rad Laboratories, Hercules, CA, USA) 
was used for electroporation under the condition of 10 kV/cm, 25 F, 
and 200 ohms (0.2-cm cuvette). The pulsed cells were immediately 
mixed with 1 ml of anaerobically stored GAM (Nissui). After 3 hours 
of anaerobic incubation, the cells were spread onto GAM agar plate 
(Nissui) containing appropriate antibiotics. The plates were incu-
bated anaerobically until colonies were visible (typically 2 to 4 days).
Construction of a host strain for determining physiological 
substrates of HMO transporters
In vivo substrate specificity of HMO transporters was examined by 
heterologously expressing the gene clusters in lnbX- and gltA-deficient 
B. longum 105-A strain with pMSK65 carrying the genes encoding 
intracellular exo-glycosidases for HMO depolymerization (Fig. 1, 
A and B) (16). An In-Fusion HD Cloning kit (Clontech Laboratories, 
Mountain View, CA, USA) was used for ligation henceforth. pMSK65 
was constructed as follows: First, the constitutive xfp promoter 
region (29) and 1,2--l-fucosidase gene of B. infantis (Blon_2335) 
were amplified by polymerase chain reaction (PCR), and the 
fragments were inserted into Pst I– and Sal I–digested pBFS38 (29), 
generating pMSK36. Then, the PCR-amplified xfp promoter region, 
N-acetylglucosaminidase gene (Blon_0459), and LNT -1,3-galactosidase 
gene (Blon_2016) were inserted into the Bgl II site of pMSK36 in 
this order, which yielded pMSK59. Last, the xfp promoter region, 
1,3/1,4--l-fucosidase gene (Blon_2336), and sialidase gene (Blon_2348) 
were amplified, and the three fragments were inserted into the Not 
I site of pMSK59 in that order, resulting in pMSK65.
The gene clusters of FL transporter-1 (Blon_0341–0343) and FL 
transporter-2 (Blon_2202–2204) from B. infantis JCM 1222T and 
FL transporter-2 (BBKW_1838–1840) from B. kashiwanohense 
JCM 15439T that were amplified by PCR were inserted into the Nde 
I site of pJW241 (30) (a compatible plasmid with pMSK65) under 
the control of the xfp promoter. The resulting plasmids were introduced 
into pMSK65-harboring B. longum 105-A lnbX gltA strain. The 
primers used for strain construction are listed in table S3 (nos. 1 to 
12). The PCR-amplified fragments were sequenced to ensure that 
no base changes other than those planned had occurred.
Targeted gene disruption in B. longum 105-A and B. infantis 
JCM 1222T
Homologous recombination was used for targeted gene disruption 
on the genomes of B. longum 105-A lnbX (20) and B. infantis JCM 
1222T. Insertional inactivation of the FL2-BP gene in B. infantis 
JCM 1222T (FL2-BPINS) was accomplished by a single crossover 
event using a suicide vector as described previously (fig. S2B) (19). 
The suicide plasmid used for the inactivation was constructed by 
ligating the PCR-amplified internal region of the FL2-BP gene from 
B. infantis with 2.0-kb Bam HI–digested fragment of pBS423 carrying 
pUC ori and Sp resistance gene (SpR) (31). The primers used are 
listed in table S3 (no. 21).
Markerless gene deletion of gltA in B. longum 105-A lnbX 
and FL transporter-1 (Blon_0341–0343) and FL transporter-2 
(Blon_2202–2204) genes in B. infantis JCM 1222T was conducted 
by two-step genomic rearrangement events (fig. S2A) (31). The 
region containing pTB4 repA ori and pUC ori of the conditional 
replication plasmid pBS423 repA (31) was ligated with PCR-amplified 
upstream and downstream regions of the target genes, between 
which the SpR gene carrying mutant loxP sites at both ends (lox71-
Sp-lox66) (32) was inserted. The resulting plasmid was first integrated 
into the genome by a single crossover event. Then, the second cross-
over event was induced by supplying RepA in trans (31). Last, the 
SpR gene was excised by expressing Cre recombinase from pBFS109 
that was constructed by inserting the PCR-amplified cre gene under 
the control of a cscBA promoter (29) (GenBank accession no. MK854762) 
into the Nsi I and Not I sites of pBFS38 (29). Disruption at the 
desired locus was confirmed by genomic PCR and direct sequencing 
of the amplified fragment. pBFS109 was cured by adding rifampicin 
to the medium as described previously (31). The primers used are 
listed in table S3 (nos. 13 to 20 and 22).
Growth competition assay
The WT and double mutant (FL1 FL2-BPINS) strains of B. infantis 
JCM 1222T were used for competitive growth assays. Cells grown 
overnight in GAM (Nissui) were separately harvested, and the two 
cell suspensions were added to MRS-CS supplemented with 0.5% (w/v) 
GOSs, 2′-FL, or purified HMO mixture to OD600 = 0.002. After incu-
bation at 37°C for 24 hours, the culture was diluted by 100-fold with 
a new MRS-CS supplemented with the same sugar. Following a further 
24-hour incubation, the genomic DNA was extracted from the culture 
and used for quantification with TaqMan-based assay (Probe qPCR 
Mix, TaKaRa Bio, Kusatsu, Japan). Primers and a specific probe are 
listed in table S3 (nos. 23 and 24). The standard curves were created 
using the genomic DNAs of the respective strains. The assays were 
conducted in biological triplicates, and the data are expressed as 
means ± SD.
Expression and purification of recombinant FL1-BP and  
FL2-BP proteins
FL1-BP and FL2-BP from B. infantis JCM 1222T were expressed as both 
nontagged and histidine (His)–tagged fusions. The genes encoding 
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the mature proteins of FL1-BP (amino acid residues 32 to 469) 
and FL2-BP (amino acid residues 26 to 460) were amplified by 
PCR and inserted into the Nde I and Xho I sites of pCDF23 (33) 
using primers enlisted in table S3 (nos. 30 and 31). The resulting 
sequence-verified plasmids were introduced into E. coli BL21 
(DE3) lacZ carrying pRARE2 (19). Transformants were grown 
in LB medium supplemented with Sp and Cm to OD600 = 0.5, and 
thereafter, the protein expression was induced with isopropyl 
-d-thiogalactopyranoside (IPTG) at a final concentration of 0.1 mM. 
Following overnight incubation at 18°C, cells were harvested, resus-
pended in 50 mM sodium phosphate buffer (pH 7.0), and disrupted 
by sonication. The clear lysate obtained by centrifugation was 80% 
saturated by ammonium sulfate, and the resulting supernatant 
(>80% fraction) was dialyzed against 20 mM tris-HCl (pH 8.0). 
Retentates were concentrated with an Amicon Ultra 10 K centrifugal 
device (Merck Millipore, Burlington, MA, USA) and loaded onto a 
Mono Q 5/50 GL column (GE Healthcare, Chicago, IL, USA), and 
proteins were eluted by a linear gradient of 0 to 1 M NaCl in the 
same buffer. The eluted fractions containing FL-BPs were combined, 
further purified by size exclusion chromatography using a Superdex 
200 Increase 10/300 GL column (GE Healthcare), and used for ITC 
analysis.
His-tagged proteins were prepared as follows: The genes encoding 
FL1-BP (amino acid residues 29 to 469) and FL2-BP (amino acid residues 
24 to 460) were PCR-amplified and inserted into Nco I and Eco RI sites 
of pETM11 [a gift from G. Stier, EMBL (European Molecular Biology 
Laboratory), Center for Biochemistry, Heidelberg, Germany]. The primers 
used are listed in table S3 (nos. 32 and 33). The recombinant proteins 
were produced in E. coli BL21 (DE3) as an N-terminal fusion with a 
TEV (tobacco etch virus nuclear inclusion a endopeptidase)–cleavable 
His-tag separated by a three–amino acid insertion (Gly-Ala-Met). Protein 
production was performed by growing the cells in LB medium con-
taining kanamycin at 37°C to OD600 = 0.5; thereafter, the temperature 
was reduced to 21°C, expression was induced by addition of IPTG 
to 0.1 mM, and growth was continued for 16 hours. Cells were harvested 
by centrifugation, resuspended in binding buffer [10 mM Hepes 
(pH 7.4), 500 mM NaCl, 10 mM imidazole, 10% glycerol, and 0.5 mM 
dithiothreitol], and lysed by a single passage through a high-pressure 
homogenizer. After centrifugation, clarified lysates were applied 
onto a 5-ml HisTrap HP column (GE Healthcare) and purified as 
recommended by the manufacturer. Eluted pure fractions were 
pooled, concentrated as described above, applied to a HiLoad Superdex 
G75 26/60 gel filtration column (GE Healthcare), and eluted with 
10 mM MES buffer (pH 6.5) at 1 ml/min. His-tags were cleaved using 
TEV protease using a standard protocol. Cleaved proteins were re-
covered after passing through a HisTrap HP column (1 ml) pre- 
equilibrated with the binding buffer, concentrated as described above, 
and stored at 4°C until further use. These protein preparations were 
used for SPR analysis and crystallization. Purity was assessed by 
SDS–polyacrylamide gel electrophoresis. The protein concentration 
was determined spectrophotometrically at 280 nm using a theoretical 
absorption coefficient of 77,810 M−1 cm−1 for FL1-BP and 81,820 M−1 
cm−1 for FL2-BP, calculated based on the amino acid sequence.
Binding studies
ITC analysis
Binding thermodynamics of FL1-BP and FL2-BP to carbohydrate 
ligands were analyzed with MicroCal iTC200 (GE Healthcare). The 
proteins (45 to 250 M) were extensively dialyzed against 10 mM 
sodium phosphate buffer (pH 6.5) and thereafter titrated with dif-
ferent ligands (2 to 10 mM) using 20 injections (0.4 l for the first 
injection and 2.0 l for the following injections separated by 180 s). 
Data were collected with the c values (c = n [the number of binding 
sites] × protein concentration × Ka) between 1 and 27. The ITC 
thermograms were corrected for the heat of dilution (measured by 
injecting the ligands into the buffer) and analyzed using MicroCal 
Origin 7.0. A binding model for one set of equivalent sites was fitted 
to the data to determine association constant (Ka), molar binding 
enthalpy (H), and binding stoichiometry (n). The data are reported 
as means ± SD of duplicate experiments.
SPR analysis
Affinities of FL1-BP and FL2-BP to oligosaccharides were also de-
termined using a Biacore T100 instrument (GE Healthcare). The 
proteins were diluted in 10 mM sodium acetate (pH 4.1) to 2.0 μM and 
immobilized on a CM5 sensor chip using a random amine coupling 
kit (GE Healthcare) to a density of 3500 response units. Sensorgrams 
were recorded and analyzed as described (34). Experiments were 
performed in duplicates in the range between 1 and 160 M for 
2′-FL, 1 and 100 M for 3-FL, and 10 and 1 mM for LDFT.
Crystallization and structure determination of FL2-BP
Crystals were only obtained in the presence of 10 mM 2′-FL or 3-FL 
by vapor diffusion in hanging or sitting drops and grew for 1 week 
at room temperature at a 1:1 ratio of the native FL2-BP or the sele-
nomethionine (SeMet)–labeled protein [100 mg/ml in 10 mM MES 
(pH 6.5) and 150 mM NaCl] and reservoir solution [100 mM MES 
(pH 6.5), 25% polyethylene glycol 500 monomethyl ether (PEG-
500MME), and 10 mM ZnSO4]. The SeMet-labeled protein was 
expressed as previously described (35) and purified similarly as de-
scribed for WT protein as above. The crystals were flash-frozen in 
liquid nitrogen without cryoprotectant in nylon loops. Diffraction 
data were collected to a maximum resolution of 2.1 Å for SeMet- 
labeled FL2-BP complexed with 2′-FL, 1.3 Å for FL2-BP complexed with 
2′-FL, and 1.4 Å for FL2-BP complexed with 3-FL at the European 
Synchrotron Radiation Facility (ESRF) beamlines, Grenoble, France. 
All datasets were processed with XDS (36). The SeMet-labeled FL2-BP 
crystal diffracted to ~1 Å, but we were not able to process it beyond 
2.1 Å. The structure was solved in the rhombohedral space group R3 in 
hexagonal setting (H3) using single-wavelength anomalous diffraction, 
with the experimental phase information obtained from data collected 
at the selenium K-edge. The program Phenix.AutoSol (37, 38) identified 
all selenium atoms in the 13 possible SeMet residues in the FL2-BP. An 
initial partial model was obtained with Phenix.AutoBuild (39). Further 
corrections and model building using the program Coot (40) resulted 
in a complete model, which was used in molecular replacement to 
solve the structure of FL2-BP in complex with 2′-FL. The models 
were refined using phenix.refine (41), randomly setting aside 5% of 
the reflections using identical R-free sets for all refinements. Molecular 
replacement with the protein part of FL2-BP was used to solve the 
3-FL–complexed structure. Ligand molecules were included manually 
using Coot after the protein atoms were built, and water molecules 
were added. The overall quality of all models was checked using 
MolProbity (37). Data collection and refinement statistics are shown 
in table S1. The two complexes are very similar in conformation and 
superposition of the individual models results in pairwise overall 
RMSD of 0.2 Å between aligned C atoms. The PyMOL Molecular 
Graphics System (version 1.7.2.2, Schrödinger, New York, NY, USA) 
was used to explore the models and for molecular graphics.
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Genomic conservation and phylogenetic analysis of FL1-BP 
and FL2-BP homologs
Conservation of FL1-BP and FL2-BP homologs was analyzed with 
BlastP using NCBI genomic database available on 31 August 2018 
(www.ncbi.nlm.nih.gov/). B. longum SC596 genome was also included 
in the analysis (12). For phylogenetic tree construction, we used se-
quences of homologs that span FL1-BP to FL2-BP (these proteins 
share 60% amino acid identity), i.e., the sequences that share ≥60% 
identity. On the basis of this threshold, 18 distinct sequences of FL-BP 
homologs were retrieved and aligned using MAFFT (https://mafft.
cbrc.jp/alignment/software/). The resulting multiple sequence align-
ment was used for classification using the neighbor-joining algorithm 
on the same server using a standard setting. Logo tags that represent 
the sequences of different clades were made by WebLogo (https://
weblogo.berkeley.edu/logo.cgi) based on the same alignment used to 
generate the tree.
Sample collection
Fecal samples were collected from 67 healthy Japanese subjects who 
had not taken any antibiotics for 1 month. Thirty-six healthy breast-fed 
infants (18 male and 18 female babies, average age = 2.9 ± 1.2 months, 
age range = 1.4 to 5.7 months) who were born at full term were re-
cruited from Nagao Midwife Clinic (Kyoto, Japan). Breast milk was 
donated from 32 mothers at the same day when their infant stools 
were collected. Thirty-one healthy adults (16 males and 15 non-
pregnant females who are not kin of the recruited infants, average 
age = 42.3 ± 16.8 years, age range = 21 to 75 years) were recruited 
from Ishikawa Prefectural University (Ishikawa, Japan). All samples were 
frozen immediately after collection and transferred to the laboratories. 
The samples were subjected to quantitative PCR (qPCR)–based mi-
crobial abundance analysis (infant and adult stools) and HMO 
analysis (breast milk and infant stools) as described later. All sam-
ples were blinded before data evaluation.
HMO analysis
HMOs present in breast milk, infant stools, and culture superna-
tants were fluorescence-labeled and analyzed by HPLC using the 
method described previously (11). Maltoheptaose was added as an 
internal standard to breast milk and culture supernatant, while mel-
ibiose was used for fecal HMO analysis. Analysis of culture super-
natants was carried out in technical triplicates, whereas breast milk 
and infant stool analyses were carried out once.
Quantification of 16S rRNA and FL transporter genes in feces
Stool DNA was extracted as described previously (20). The copy 
numbers of the genes attributable to FL1-BP and FL2-BP and 16S 
ribosomal RNA (rRNA) of total bacteria and genus Bifidobacterium 
in fecal DNA were quantified using an SYBR Green system (TB 
Green Premix Ex Taq II, TaKaRa Bio). Relative abundance (%) was 
calculated by dividing the copy numbers of the transporter genes or 
genus Bifidobacterium-specific 16S rRNA gene by the total bacterial 
16S rRNA gene copies. The average values of technical duplicates 
(<6% difference of threshold cycle) were reported. The primers 
used for qPCR analysis were listed in table S3 [nos. 25 to 29; note 
that two different primer pairs were used for quantifying FL2-BP 
orthologs (clusters I and II and cluster III)] (Fig. 3D and fig. S6C). 
Standard curves were created using B. infantis JCM 1222T and 
B. kashiwanohense JCM 15439T genomic DNAs as templates. The 
detection limits of our qPCR system for FL1-BP and FL2-BP genes 
were 1.1 × 104 and 6.3 × 104 copies/g feces, respectively, while that 
for genus Bifidobacterium was 2.1 × 105 copies/g feces. The specificity 
of each primer set was confirmed before the analysis.
Metagenome data mining
The dataset of fecal microbiome shotgun sequencing was obtained 
from MG-RAST version 4.0.3 (http:// metagenomics.anl.gov/) under 
accession no. “qiime:621” (3). The obtained sequences were quality- 
trimmed and quality-filtered with custom Perl and Python scripts 
and publicly available software as follows. After removing sequences 
less than 60 nucleotide or containing degenerate base (N), all dupli-
cates (a known artifact of pyrosequencing), defined as sequences in 
which the initial 20 nucleotides are identical and that share an overall 
identity more than 97% throughout the length of the shortest read, 
were removed by CD-HIT-454 (42). Host DNA was removed by 
mapping to the Genome Reference Consortium human build 38 
(GRCh38) with Burrows-Wheeler Aligner (BWA) algorithm using 
maximal exact match (MEM) option (43). Consequently, the shotgun 
sequencing data of 132,556 ± 76,952 reads per sample (means ± SD) for 
83 individuals residing in the United States (n = 50), Malawi (n = 18), 
and Venezuela (n = 15), which are composed of breast-fed (n = 34) 
and formula-fed (n = 27) infants (≤1 year old) and adults (n = 22, 
≥18 years old), were used for the analysis. The quality filtered reads 
were mapped to FL1-BP and FL2-BP homologs shown in Fig. 3D, in 
which redundant mapping to the reference genes was counted as 
a single by BWA using MEM option. The relative abundance (%) 
was calculated by dividing the mapped read counts with total read 
counts. Data of bifidobacterial abundance in fecal samples were also 
obtained from MG-RAST with the same accession number.
Ethical consideration
This study was reviewed and approved by the Ethics Committees of 
Kyoto University (R0046), the University of Shiga Prefecture (71-3), 
and the Ishikawa Prefectural University (2016-2) and was performed 
in accordance with the Declaration of Helsinki. Informed consent 
was obtained from all donors except for infants. Infant stools were 
collected with their mother’s consent.
Statistical analysis
Statistical analyses were performed using Bell Curve for Excel (Social 
Survey Research Information, Tokyo, Japan). The Student’s two-tailed 
t test and Mann-Whitney U test were used for determining the sta-
tistical significance. For multiple comparisons, Bonferroni correc-
tion was applied. Spearman’s rank correlation coefficient analysis 
was used for examining the relationship between the relative abun-
dances of the transporter genes and the genus Bifidobacterium and 
between the fecal HMO concentrations and the relative abundance 
of the transporter genes. A P value of less than 0.05 was considered 
statistically significant.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/8/eaaw7696/DC1
Fig. S1. Representative HMO molecules analyzed in this study.
Fig. S2. Schematic representation of two different gene disruption methods used in this study.
Fig. S3. Evaluation of the HMO transporter–heterologous expression system.
Fig. S4. ITC and SPR analyses of SBPs of FL transporter-1 and -2.
Fig. S5. Structural basis of the dual recognition of 2′-FL and 3-FL by FL2-BP from B. infantis JCM 1222T.
Fig. S6. Phylogenetic and structural analyses revealed the signature sequences that dictate 
specificity difference between FL1-BP and FL2-BP homologs.
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Fig. S7. HMO consumption analysis using samples collected from 32 mother-infant pairs.
Table S1. Data collection and refinement statistics for the SBP of FL transporter-2 from  
B. infantis JCM 1222T (FL2-BP).
Table S2. Polar contacts between FL2-BP and FL molecules.
Table S3. Primers and probes used in this study.
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